This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Maxygen Announces Second Quarter 2012 Financial Results And Business Update

Stocks in this article: MAXY

About Maxygen

Maxygen is a biotechnology company that has historically focused on the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. Maxygen continues to retain all rights to its MAXY-G34 product candidate, a next-generation pegylated, granulocyte colony stimulating factor, or G-CSF, for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome. For more information, please visit our website at www.maxygen.com.

Cautionary Statement Regarding Maxygen Forward-Looking Statements

This document contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations and beliefs of Maxygen’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Such risks and uncertainties include, but are not limited to, the following: the estimated tax treatment of the planned cash distribution for U.S. Federal tax purposes, our ability or plans to identify and consummate a strategic transaction for our MAXY-G34 program or to recommence and/or continue the development of our MAXY-G34 product candidate for any indication; strategic alternatives and transactions with respect to our company and the timing, likelihood and outcome thereof; our implementation, or our failure to implement, any additional distributions of our cash resources to stockholders; our ability to continue operations and our estimates for future performance and financial position of the company; and our ability to retain key employees to maintain our ongoing operations. Additional risk factors are more fully discussed in Maxygen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, to be filed with the SEC on the date hereof, including under the caption “Risk Factors,” and in Maxygen’s other periodic reports filed with the SEC, all of which are available from Maxygen or from the SEC’s website ( www.sec.gov). Maxygen is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise, except to the extent required by applicable law.

       

Selected Consolidated Financial Information

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

 
Three months ended Six months ended
June 30, June 30,
             
  2011       2012       2011       2012  
 
(unaudited)
Technology and license revenue $ 3 $ 30,000 $ 3 $ 30,006
Operating expenses:
Research and development 783 1,350 65
General and administrative   2,638     2,418     5,778     5,185  
Total operating expenses 3,421 2,418 7,128 5,250
 
Income (loss) from operations (3,418 ) 27,582 (7,125 ) 24,756
Gain on distribution of equity securities 164 68 249 143
Interest and other income (expense), net   432     (10 )   309     169  
Income (loss) from continuing operations before income taxes (2,822 ) 27,640 (6,567 ) 25,068
Income tax benefit (expense)   638     (70 )   2,374     (70 )
Income (loss) from continuing operations (2,184 ) 27,570 (4,193 ) 24,998
Discontinued operations:
Income (loss) from discontinued operations (4,735 ) 1,302
Gain on sale of discontinued operations 62,219 62,219
Income tax expense for discontinued operations   (1,521 )       (3,038 )    
Income from discontinued operations, net of taxes   55,963         60,483      
Net income 53,779 27,570 56,290 24,998
Net income (loss) attributable to non-controlling interests   (742 )   450     310     450  
Net income attributable to Maxygen, Inc. $ 54,521   $ 27,120   $ 55,980   $ 24,548  
Basic net income (loss) per share:
Attributable to Maxygen, Inc. from continuing operations $ (0.05 ) $ 1.00 $ (0.15 ) $ 0.90
Attributable to Maxygen, Inc. from discontinued operations $ 1.91 $ $ 2.06 $
Attributable to Maxygen, Inc. $ 1.86 $ 1.00 $ 1.91 $ 0.90
Diluted net income (loss) per share:
Attributable to Maxygen, Inc. from continuing operations $ (0.05 ) $ 0.99 $ (0.15 ) $ 0.90
Attributable to Maxygen, Inc. from discontinued operations $ 1.91 $ $ 2.06 $
Attributable to Maxygen, Inc. $ 1.86 $ 0.99 $ 1.91 $ 0.90
 
Shares used in basic net income (loss) per share calculations 29,344 27,250 29,284   27,241
 
Shares used in diluted net income (loss) per share calculations 29,344 27,388 29,284 27,424
 

Consolidated Balance Sheet Data

(in thousands)

   
December 31, June 30,
2011

(Note 1)

2012

(Unaudited)

 
 
Cash, cash equivalents and short-term investments $ 159,571 $ 182,723
Available-for-sale investment in equity securities 2,478 1,599
Prepaid expenses and other assets   2,584   2,341
Total assets $ 164,633 $ 186,663
 
Distribution payable $ 1,076 $ 564
Other liabilities 2,613 2,000
Stockholders' equity   160,944   184,099
Total liabilities and stockholders’ equity $ 164,633 $ 186,663
 

Note 1: Derived from consolidated audited financial statements as of December 31, 2011.





5 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASDAQ 4,791.63 +4.3130 0.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs